Healthcare ETF: Treatment Breakthroughs Make China A Medical Destination
· seekingalpha.com
During the first half of 2026, Chinese innovative drug developers completed 81 overseas licensing transactions with an aggregate potential deal value of approximately $110 billion.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...